Previous 10 | Next 10 |
Updates best practice advice to support non-endoscopic esophageal precancer screening and significantly expands target population to include, for the first time, at-risk patients without chronic heartburn symptoms Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lu...
Agreements with three PPOs and a specialized laboratory network expand Lucid’s reach, providing in-network access and payment for its EsoGuard ® DNA test to millions of additional covered lives Lucid Diagnostics Inc. (Nasdaq: LUCD ) (“Lucid...
Company conference call and webcast at 4:30 PM EDT Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced t...
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced that Dr. Lishan Aklog, Chair...
PAVmed established an interesting hub and spoke business model with joint services and selling stakes in commercially ready technologies. This opens up new financing streams and potentially a lot of value creation for PAVmed shareholders. But near-term, the viability depends on th...
PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (“PAVmed”), a diversified commercial-stage medical technology company, and its majority-owned subsidiary Lucid Diagnostics Inc. ( Nasdaq: LUCD ) (“Lucid”), a commercial-stage cancer prevention medical...
Lucid Diagnostics Inc. (LUCD) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Adrian Miller – Vice President-Investor Relations Lishan Aklog – Chairman and Chief Executive Officer Dennis McGrath – Chief Financial Officer Conference Call Parti...
Lucid Diagnostics press release (NASDAQ:LUCD): Q1 Non-GAAP EPS of -$0.23 beats by $0.01. Revenue of $0.2M misses by $0.25M. For further details see: Lucid Diagnostics Non-GAAP EPS of -$0.23 beats by $0.01, revenue of $0.2M misses by $0.25M
Conference call to be held today at 4:30 PM EDT Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq...
Lucid’s first commercial payer agreement provides in-network access and payment for its EsoGuard ® DNA test to over 8 million covered lives Lucid Diagnostics Inc. (Nasdaq: LUCD ) (“Lucid”, the “Company”) a commercial-st...
News, Short Squeeze, Breakout and More Instantly...
Lucid Diagnostics Inc. Company Name:
LUCD Stock Symbol:
NASDAQ Market:
Lucid Diagnostics Inc. Website:
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume PR Newswire Quarterly EsoGuard ® test volume increased 31 percent sequentially NEW YORK , July 23, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("L...
Lucid Diagnostics Launches New Corporate Website PR Newswire NEW YORK , July 11, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-ow...
Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population PR Newswire Prospective screening study demonstrates excellent EsoGuard s...